SecurityFNBG / FNB Bancorp (302515101)
CEOMCGRAW THOMAS C
IndustryState Commercial Banks
Institutional Owners48
Institutional Shares1,739,031 - 23.25%
Common Shares Outstanding7,480,538 shares (as of 2018-03-31)
Institutional Value$ 77,390,000 USD
Related FBIP / FNB Bancorp, Inc.

Institutional Stock Ownership and Shareholders()

FNB Bancorp (NASDAQ:FNBG) has 48 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,739,031 shares. Largest shareholders include Brown Trout Management, LLC, Vanguard Group Inc, BlackRock Inc., Banc Funds Co Llc, State Street Corp, Renaissance Technologies LLC, Northern Trust Corp, San Francisco Sentry Investment Group (ca), Dimensional Fund Advisors Lp, and Deutsche Bank Ag\.
FNB Bancorp (NASDAQ:FNBG) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-10 13F-HR GREAT WEST LIFE ASSURANCE CO /CAN/ 32 1
2018-05-11 13F-HR BANC FUNDS CO LLC 313,041 172,641 -44.85 11,422,867 6,351 -99.94
2018-04-26 13F-HR RAMSEY QUANTITATIVE SYSTEMS 354 619 74.86 13 23 76.92
2018-05-14 13F-HR Renaissance Technologies LLC 24,776 56,800 129.25 904 2,090 131.19
2018-05-15 13F-HR Parallax Volatility Advisers, L.P. 1,596 0 -100.00 58 0 -100.00
2018-05-17 13F-HR Legal & General Group Plc 1,021 1,021 0.00 37 38 2.70
2018-04-12 13F-HR ACADIAN ASSET MANAGEMENT LLC 13,078 0 -100.00 478 0 -100.00
2018-05-11 13F-HR Russell Investments Group, Ltd. 1,448 0 -100.00 54 0 -100.00
2018-05-14 13F-HR TIAA CREF INVESTMENT MANAGEMENT LLC 13,027 13,027 0.00 475 479 0.84
2018-05-10 13F-HR NEW YORK STATE COMMON RETIREMENT FUND 5,700 5,700 0.00 208 210 0.96
2018-05-15 13F-HR Walleye Trading LLC 10,850 10,850 0.00 396 399 0.76
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 220 220 0.00 8 8 0.00
2018-04-20 13F-HR STRS OHIO 500 500 0.00 18 18 0.00
2018-04-20 13F-HR FIRST QUADRANT L P/CA 3,908 3,908 0.00 143 144 0.70
2018-05-09 13F-HR BlackRock Inc. 229,329 228,108 -0.53 8,368 8,393 0.30
2018-05-07 13F-HR AMERICAN INTERNATIONAL GROUP INC 3,573 3,447 -3.53 130 127 -2.31
2018-05-11 13F-HR STIFEL FINANCIAL CORP 28,404 9,943 -64.99 1,031 365 -64.60
2018-05-15 13F-HR UBS Group AG 813 175 -78.47 30 6 -80.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 19,943 20,605 3.32 728 758 4.12
2018-04-13 13F-HR BANK OF MONTREAL /CAN/ 500 0 -100.00 18 0 -100.00
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 17,867 39,432 120.70 652 1,451 122.55
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 1,783 0 -100.00 65 0 -100.00
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 8,700 8,700 0.00 318 321 0.94
2018-05-15 13F-HR Ativo Capital Management LLC 19,000 699
2018-05-11 13F-HR CITIGROUP INC 787 1,115 41.68 29 41 41.38
2018-05-11 13F-HR BNP PARIBAS ARBITRAGE, SA 1,301 365 -71.94 47,473 13,428 -71.71
2018-05-14 13F-HR TEACHERS ADVISORS INC 9,206 9,206 0.00 336 339 0.89
2018-05-15 13F-HR Round Hill Asset Management 9,200 8,920 -3.04 336 328 -2.38
2018-05-10 13F-HR JP Morgan Chase & Co 1,145 1,085 -5.24 42 40 -4.76
2018-05-11 13F-HR Delpha Capital Management, Llc 16 0 -100.00 1 0 -100.00
2018-05-15 13F-HR SPRINGBOK CAPITAL MANAGEMENT, LLC 8,000 13,000 62.50 292 478 63.70
2018-05-15 13F-HR Ameritas Investment Partners, Inc. 466 466 0.00 17 17 0.00
2018-05-15 13F-HR CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 8,350 8,350 0.00 305 307 0.66
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 16,323 16,843 3.19 595 619 4.03
2018-05-15 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 11,208 13,105 16.93 409 482 17.85
2018-05-15 13F-HR PANAGORA ASSET MANAGEMENT INC 10,264 9,358 -8.83 375 344 -8.27
2018-05-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 12,477 459
2018-05-15 13F-HR STATE STREET CORP 61,254 80,623 31.62 2,235 2,965 32.66
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 5,031 5,079 0.95 183 187 2.19
2018-05-09 13F-HR Brown Trout Management, LLC 250,288 479,080 91.41 9,133 17,625 92.98
2018-05-09 13F-HR NORTHERN TRUST CORP 45,594 50,688 11.17 1,664 1,865 12.08
2018-05-15 13F-HR VANGUARD GROUP INC 255,414 273,301 7.00 9,320 10,054 7.88
2018-05-08 13F-HR Parallel Advisors, LLC 18 18 0.00 1 1 0.00
2018-05-14 13F-HR DLD Asset Management, LP 10,000 368
2018-05-08 13F-HR O'SHAUGHNESSY ASSET MANAGEMENT, LLC 5,533 0 -100.00 202 0 -100.00
2018-05-01 13F-HR WEDBUSH SECURITIES INC 8,183 6,608 -19.25 299 243 -18.73
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 828 505 -39.01 30 19 -36.67
2018-05-15 13F-HR DEUTSCHE BANK AG\ 26,996 31,267 15.82 982 1,149 17.01
2018-05-04 13F-HR SAN FRANCISCO SENTRY INVESTMENT GROUP (CA) 50,404 50,404 0.00 1,839 1,854 0.82
2018-05-14 13F-HR RAYMOND JAMES & ASSOCIATES 22,029 21,912 -0.53 804 806 0.25
2018-05-15 13F-HR BARCLAYS PLC 856 1,134 32.48 32 42 31.25
2018-05-15 13F-HR Bank of New York Mellon Corp 22,269 23,726 6.54 812 873 7.51
2018-05-03 13F-HR SG Americas Securities, LLC 0 2,812 0 103
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 359 1,066 196.94 13 39 200.00
2018-05-14 13F-HR MORGAN STANLEY 11,444 11,790 3.02 417 434 4.08

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 302515101